256 related articles for article (PubMed ID: 17208339)
1. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).
Beutels P; Thiry N; Van Damme P
Vaccine; 2007 Feb; 25(8):1355-67. PubMed ID: 17208339
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
[TBL] [Abstract][Full Text] [Related]
6. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
Giglio N; Micone P; Gentile A
Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
[TBL] [Abstract][Full Text] [Related]
7. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
Marchetti M; Colombo GL
Vaccine; 2005 Aug; 23(37):4565-76. PubMed ID: 15992969
[TBL] [Abstract][Full Text] [Related]
10. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].
Postma MJ; Heijnen ML; Beutels P; Jager JC
Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224
[TBL] [Abstract][Full Text] [Related]
11. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.
Giglio ND; Cane AD; Micone P; Gentile A
Vaccine; 2010 Mar; 28(11):2302-10. PubMed ID: 20064478
[TBL] [Abstract][Full Text] [Related]
15. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
[TBL] [Abstract][Full Text] [Related]
16. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
[TBL] [Abstract][Full Text] [Related]
17. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
Haber M; Barskey A; Baughman W; Barker L; Whitney CG; Shaw KM; Orenstein W; Stephens DS
Vaccine; 2007 Jul; 25(29):5390-8. PubMed ID: 17583392
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of pneumococcal conjugate vaccination in Finland.
Salo H; Sintonen H; Nuorti JP; Linna M; Nohynek H; Verho J; Kilpi T
Scand J Infect Dis; 2005; 37(11-12):821-32. PubMed ID: 16308215
[TBL] [Abstract][Full Text] [Related]
19. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.
Rubin JL; McGarry LJ; Strutton DR; Klugman KP; Pelton SI; Gilmore KE; Weinstein MC
Vaccine; 2010 Nov; 28(48):7634-43. PubMed ID: 20883739
[TBL] [Abstract][Full Text] [Related]
20. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
